FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2100173675> ?p ?o ?g. }

• W2100173675 endingPage "110" @default.
• W2100173675 startingPage "103" @default.
• W2100173675 abstract "Prior studies have demonstrated that elevated aldosterone concentrations are an independent risk factor for death in patients with cardiovascular disease. Limited studies, however, have evaluated systematically the association between serum aldosterone and adverse events in the setting of chronic kidney disease. We investigated the association between serum aldosterone and death and end-stage renal disease in 3866 participants from the Chronic Renal Insufficiency Cohort. We also evaluated the association between aldosterone and incident congestive heart failure and atherosclerotic events in participants without baseline cardiovascular disease. Cox proportional hazards models were used to evaluate independent associations between elevated aldosterone concentrations and each outcome. Interactions were hypothesized and explored between aldosterone and sex, race, and the use of loop diuretics and renin–angiotensin–aldosterone system inhibitors. During a median follow-up period of 5.4 years, 587 participants died, 743 developed end-stage renal disease, 187 developed congestive heart failure, and 177 experienced an atherosclerotic event. Aldosterone concentrations (per SD of the log-transformed aldosterone) were not an independent risk factor for death (adjusted hazard ratio, 1.00; 95% confidence interval, 0.93–1.12), end-stage renal disease (adjusted hazard ratio, 1.07; 95% confidence interval, 0.99–1.17), or atherosclerotic events (adjusted hazard ratio, 1.04; 95% confidence interval, 0.85–1.18). Aldosterone was associated with congestive heart failure (adjusted hazard ratio, 1.21; 95% confidence interval, 1.02–1.35). Among participants with chronic kidney disease, higher aldosterone concentrations were independently associated with the development of congestive heart failure but not for death, end-stage renal disease, or atherosclerotic events. Further studies should evaluate whether mineralocorticoid receptor antagonists may reduce adverse events in individuals with chronic kidney disease because elevated cortisol levels may activate the mineralocorticoid receptor." @default.
• W2100173675 created "2016-06-24" @default.
• W2100173675 creator A5006968882 @default.
• W2100173675 creator A5016894949 @default.
• W2100173675 creator A5021835685 @default.
• W2100173675 creator A5033653079 @default.
• W2100173675 creator A5046831441 @default.
• W2100173675 creator A5047317486 @default.
• W2100173675 creator A5059631475 @default.
• W2100173675 creator A5060357056 @default.
• W2100173675 creator A5071585977 @default.
• W2100173675 creator A5075956672 @default.
• W2100173675 creator A5085683611 @default.
• W2100173675 creator A5091381220 @default.
• W2100173675 date "2014-07-01" @default.
• W2100173675 modified "2023-10-10" @default.
• W2100173675 title "Serum Aldosterone and Death, End-Stage Renal Disease, and Cardiovascular Events in Blacks and Whites" @default.
• W2100173675 cites W138298882 @default.
• W2100173675 cites W1965783061 @default.
• W2100173675 cites W1966041879 @default.
• W2100173675 cites W1987834053 @default.
• W2100173675 cites W1991297728 @default.
• W2100173675 cites W1992409198 @default.
• W2100173675 cites W1992967220 @default.
• W2100173675 cites W2000060059 @default.
• W2100173675 cites W2008704689 @default.
• W2100173675 cites W2017554373 @default.
• W2100173675 cites W2019270553 @default.
• W2100173675 cites W2020699761 @default.
• W2100173675 cites W2022933863 @default.
• W2100173675 cites W2026881482 @default.
• W2100173675 cites W2031706977 @default.
• W2100173675 cites W2034587587 @default.
• W2100173675 cites W2039493274 @default.
• W2100173675 cites W2045516356 @default.
• W2100173675 cites W2055562672 @default.
• W2100173675 cites W2056503496 @default.
• W2100173675 cites W2056976690 @default.
• W2100173675 cites W2087442147 @default.
• W2100173675 cites W2098347923 @default.
• W2100173675 cites W2113690088 @default.
• W2100173675 cites W2121332703 @default.
• W2100173675 cites W2123021239 @default.
• W2100173675 cites W2130472485 @default.
• W2100173675 cites W2131442239 @default.
• W2100173675 cites W2134542881 @default.
• W2100173675 cites W2144751334 @default.
• W2100173675 cites W2145632027 @default.
• W2100173675 cites W2148983669 @default.
• W2100173675 cites W2152798629 @default.
• W2100173675 cites W2155101891 @default.
• W2100173675 cites W2159602627 @default.
• W2100173675 cites W2165526282 @default.
• W2100173675 cites W2166195280 @default.
• W2100173675 cites W2170880252 @default.
• W2100173675 cites W2323458614 @default.
• W2100173675 cites W2475261460 @default.
• W2100173675 doi "https://doi.org/10.1161/hypertensionaha.114.03311" @default.
• W2100173675 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4089190" @default.
• W2100173675 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24752431" @default.
• W2100173675 hasPublicationYear "2014" @default.
• W2100173675 type Work @default.
• W2100173675 sameAs 2100173675 @default.
• W2100173675 citedByCount "27" @default.
• W2100173675 countsByYear W21001736752015 @default.
• W2100173675 countsByYear W21001736752016 @default.
• W2100173675 countsByYear W21001736752017 @default.
• W2100173675 countsByYear W21001736752018 @default.
• W2100173675 countsByYear W21001736752019 @default.
• W2100173675 countsByYear W21001736752020 @default.
• W2100173675 countsByYear W21001736752021 @default.
• W2100173675 countsByYear W21001736752022 @default.
• W2100173675 countsByYear W21001736752023 @default.
• W2100173675 crossrefType "journal-article" @default.
• W2100173675 hasAuthorship W2100173675A5006968882 @default.
• W2100173675 hasAuthorship W2100173675A5016894949 @default.
• W2100173675 hasAuthorship W2100173675A5021835685 @default.
• W2100173675 hasAuthorship W2100173675A5033653079 @default.
• W2100173675 hasAuthorship W2100173675A5046831441 @default.
• W2100173675 hasAuthorship W2100173675A5047317486 @default.
• W2100173675 hasAuthorship W2100173675A5059631475 @default.
• W2100173675 hasAuthorship W2100173675A5060357056 @default.
• W2100173675 hasAuthorship W2100173675A5071585977 @default.
• W2100173675 hasAuthorship W2100173675A5075956672 @default.
• W2100173675 hasAuthorship W2100173675A5085683611 @default.
• W2100173675 hasAuthorship W2100173675A5091381220 @default.
• W2100173675 hasBestOaLocation W21001736751 @default.
• W2100173675 hasConcept C126322002 @default.
• W2100173675 hasConcept C134018914 @default.
• W2100173675 hasConcept C164705383 @default.
• W2100173675 hasConcept C207103383 @default.
• W2100173675 hasConcept C2778198053 @default.
• W2100173675 hasConcept C2778525890 @default.
• W2100173675 hasConcept C2778653478 @default.
• W2100173675 hasConcept C2779134260 @default.
• W2100173675 hasConcept C3019040382 @default.
• W2100173675 hasConcept C44249647 @default.
• W2100173675 hasConcept C50382708 @default.

• next